BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jarnagin W, Chapman WC, Curley S, D'Angelica M, Rosen C, Dixon E, Nagorney D;  American Hepato-Pancreato-Biliary Association;  Society of Surgical Oncology;  Society for Surgery of the Alimentary Tract. Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford). 2010;12:302-310. [PMID: 20590903 DOI: 10.1111/j.1477-2574.2010.00182.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Munene G, Vauthey JN, Dixon E. Summary of the 2010 AHPBA/SSO/SSAT Consensus Conference on HCC. Int J Hepatol. 2011;2011:565060. [PMID: 21994863 DOI: 10.4061/2011/565060] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhong JH, Ke Y, Gong WF, Xiang BD, Ma L, Ye XP, Peng T, Xie GS, Li LQ. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 2014;260:329-340. [PMID: 24096763 DOI: 10.1097/sla.0000000000000236] [Cited by in Crossref: 215] [Cited by in F6Publishing: 144] [Article Influence: 30.7] [Reference Citation Analysis]
3 Cortese S, Morales J, Martín L, Kayser S, Colón A, Ramón E, Tellado JM. Resección hepática con trombectomía en el tratamiento del carcinoma hepatocelular con invasión vascular macroscópica. Cirugía Española 2020;98:9-17. [DOI: 10.1016/j.ciresp.2019.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wang H, Li W. Recent update on comprehensive therapy for advanced hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(8): 845-855 [PMID: 34457190 DOI: 10.4251/wjgo.v13.i8.845] [Reference Citation Analysis]
5 Szepeshazi K, Schally AV, Rick FG, Block NL, Vidaurre I, Halmos G, Szalontay L. Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II. Anticancer Drugs. 2012;23:906-913. [PMID: 22926257 DOI: 10.1097/cad.0b013e328354bd25] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
6 Zhuang L, Wen T, Xu M, Yang J, Wang W, Wu H, Zeng Y, Yan L, Wei Y, Li B. Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma. Arch Med Sci 2017;13:1383-93. [PMID: 29181069 DOI: 10.5114/aoms.2017.71066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
7 Xing M, Kokabi N, Camacho JC, Kooby DA, El-Rayes BF, Kim HS. 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness. J Comp Eff Res 2013;2:435-44. [PMID: 24236684 DOI: 10.2217/cer.13.37] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
8 Yan S, Xu D, Sun B. Combination of Radiofrequency Ablation with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis. Dig Dis Sci 2013;58:2107-13. [DOI: 10.1007/s10620-013-2570-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ethun CG, Maithel SK. Determination of Resectability. Surg Clin North Am 2016;96:163-81. [PMID: 27017857 DOI: 10.1016/j.suc.2015.12.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
10 Fernández-Placencia R, Golse N, Cano L, Allard MA, Pittau G, Ciacio O, Cunha AS, Castaing D, Salloum C, Azoulay D, Cherqui D, Samuel D, Adam R, Vibert E. Spleen volumetry and liver transient elastography: Predictors of persistent posthepatectomy decompensation in patients with hepatocellular carcinoma. Surgery 2020;168:17-24. [PMID: 32204923 DOI: 10.1016/j.surg.2020.02.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Jiang JF, Lao YC, Yuan BH, Yin J, Liu X, Chen L, Zhong JH. Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges. Oncotarget 2017;8:33911-21. [PMID: 28430610 DOI: 10.18632/oncotarget.15411] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
12 Swan RZ, Sindram D, Martinie JB, Iannitti DA. Operative microwave ablation for hepatocellular carcinoma: complications, recurrence, and long-term outcomes. J Gastrointest Surg. 2013;17:719-729. [PMID: 23404173 DOI: 10.1007/s11605-013-2164-y] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 5.4] [Reference Citation Analysis]
13 Zhong JH, Li H, Xiao N, Ye XP, Ke Y, Wang YY, Ma L, Chen J, You XM, Zhang ZY, Lu SD, Li LQ. Hepatic resection is safe and effective for patients with hepatocellular carcinoma and portal hypertension. PLoS One. 2014;9:e108755. [PMID: 25268959 DOI: 10.1371/journal.pone.0108755] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
14 Lepere V, Vanier A, Loncar Y, Lemoine L, Vaillant JC, Monsel A, Savier E, Coriat P, Eyraud D. Risk factors for pulmonary complications after hepatic resection: role of intraoperative hemodynamic instability and hepatic ischemia. BMC Anesthesiol 2017;17:84. [PMID: 28633644 DOI: 10.1186/s12871-017-0372-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
15 Bayoumi AS, Sayed A, Broskova Z, Teoh JP, Wilson J, Su H, Tang YL, Kim IM. Crosstalk between Long Noncoding RNAs and MicroRNAs in Health and Disease. Int J Mol Sci 2016;17:356. [PMID: 26978351 DOI: 10.3390/ijms17030356] [Cited by in Crossref: 137] [Cited by in F6Publishing: 140] [Article Influence: 22.8] [Reference Citation Analysis]
16 Deng L, Yang C, Li LQ, Zhong JH. Hepatic Resection Improves Long-Term Survival of Patients with Large and/or Multinodular Hepatocellular Carcinoma. J Gastrointest Surg 2015;19:2288-9. [PMID: 26464016 DOI: 10.1007/s11605-015-2965-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Page AJ, Cosgrove DC, Philosophe B, Pawlik TM. Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2014;23:289-311. [DOI: 10.1016/j.soc.2013.10.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
18 Yan W, Han P, Zhou Z, Tu W, Liao J, Li P, Liu M, Tian D, Fu Y. Netrin-1 induces epithelial-mesenchymal transition and promotes hepatocellular carcinoma invasiveness. Dig Dis Sci 2014;59:1213-21. [PMID: 24442237 DOI: 10.1007/s10620-013-3016-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
19 Burman B, Helton WS. Disparities in care for patients with curable hepatocellular carcinoma. HPB (Oxford) 2015;17:745-6. [PMID: 26278320 DOI: 10.1111/hpb.12477] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Coelho FF, Kruger JAP, Fonseca GM, Araújo RLC, Jeismann VB, Perini MV, Lupinacci RM, Cecconello I, Herman P. Laparoscopic liver resection: Experience based guidelines. World J Gastrointest Surg 2016; 8(1): 5-26 [PMID: 26843910 DOI: 10.4240/wjgs.v8.i1.5] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 47] [Article Influence: 8.8] [Reference Citation Analysis]
21 Khan AS, Fowler KJ, Chapman WC. Current surgical treatment strategies for hepatocellular carcinoma in North America. World J Gastroenterol 2014; 20(41): 15007-15017 [PMID: 25386049 DOI: 10.3748/wjg.v20.i41.15007] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
22 Ni J, Liu S, Xu L, Sun H, Chen Y. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2013;139:653-9. [DOI: 10.1007/s00432-012-1369-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
23 Nathan H, Segev DL, Mayo SC, Choti MA, Cameron AM, Wolfgang CL, Hirose K, Edil BH, Schulick RD, Pawlik TM. National trends in surgical procedures for hepatocellular carcinoma: 1998-2008. Cancer 2012;118:1838-44. [DOI: 10.1002/cncr.26501] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
24 Álvarez-Mercado AI, Caballeria-Casals A, Rojano-Alfonso C, Chávez-Reyes J, Micó-Carnero M, Sanchez-Gonzalez A, Casillas-Ramírez A, Gracia-Sancho J, Peralta C. Insights into Growth Factors in Liver Carcinogenesis and Regeneration: An Ongoing Debate on Minimizing Cancer Recurrence after Liver Resection. Biomedicines 2021;9:1158. [PMID: 34572344 DOI: 10.3390/biomedicines9091158] [Reference Citation Analysis]
25 Hsueh KC, Lee TY, Kor CT, Chen TM, Chang TM, Yang SF, Hsieh CB. The role of liver transplantation or resection for patients with early hepatocellular carcinoma. Tumour Biol. 2016;37:4193-4201. [PMID: 26490991 DOI: 10.1007/s13277-015-4243-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
26 Mostaedi R, Milosevic Z, Han HS, Khatri VP. Laparoscopic liver resection: Current role and limitations. World J Gastrointest Oncol 2012; 4(8): 187-192 [PMID: 22912914 DOI: 10.4251/wjgo.v4.i8.187] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
27 Dhir M, Melin AA, Douaiher J, Lin C, Zhen WK, Hussain SM, Geschwind JF, Doyle MB, Abou-Alfa GK, Are C. A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma. Ann Surg. 2016;263:1112-1125. [PMID: 26813914 DOI: 10.1097/sla.0000000000001556] [Cited by in Crossref: 124] [Cited by in F6Publishing: 86] [Article Influence: 24.8] [Reference Citation Analysis]
28 McNally SJ, Revie EJ, Massie LJ, McKeown DW, Parks RW, Garden OJ, Wigmore SJ. Factors in perioperative care that determine blood loss in liver surgery. HPB (Oxford). 2012;14:236-241. [PMID: 22404261 DOI: 10.1111/j.1477-2574.2011.00433.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
29 Rodríguez S, Fleck AM Jr, Mucenic M, Marroni C, Brandão A. HEPATOCELLULAR CARCINOMA PATIENTS ARE ADVANTAGED IN THE CURRENT BRAZILIAN LIVER TRANSPLANT ALLOCATION SYSTEM. A COMPETING RISK ANALYSIS. Arq Gastroenterol 2020;57:19-23. [PMID: 32294731 DOI: 10.1590/S0004-2803.202000000-05] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
30 Mills A, Thayer D, Noda C, Salter A, Tao Y, Xing M, Martin R, Ramaswamy R, Akinwande O. Thermal ablation versus surgical resection for localized hepatocellular carcinoma: a population study using the SEER database. Future Oncol 2018;14:631-45. [PMID: 29517284 DOI: 10.2217/fon-2017-0447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
31 Unek T, Karademir S, Arslan NC, Egeli T, Atasoy G, Sagol O, Obuz F, Akarsu M, Astarcioglu I. Comparison of Milan and UCSF criteria for liver transplantation to treat hepatocellular carcinoma. World J Gastroenterol 2011; 17(37): 4206-4212 [PMID: 22072852 DOI: 10.3748/wjg.v17.i37.4206] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
32 Deshpande R, O'Reilly D, Sherlock D. Improving Outcomes with Surgical Resection and Other Ablative Therapies in HCC. Int J Hepatol 2011;2011:686074. [PMID: 21994867 DOI: 10.4061/2011/686074] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
33 Kim C, Cigarroa N, Surabhi V, Ganeshan B, Pillai AK. Retrospective CT/MRI Texture Analysis of Rapidly Progressive Hepatocellular Carcinoma. J Pers Med 2020;10:E136. [PMID: 32967100 DOI: 10.3390/jpm10030136] [Reference Citation Analysis]
34 Garden OJ. Pushing the limits of surgical management in patients with hepatocellular carcinoma. Br J Surg 2011;98:1183-4. [PMID: 21792847 DOI: 10.1002/bjs.7677] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
35 Ramesh H. Resection for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S90-S96. [PMID: 25755617 DOI: 10.1016/j.jceh.2014.07.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
36 Seshadri RM, Besur S, Niemeyer DJ, Templin M, McKillop IH, Swan RZ, Martinie JB, Russo MW, Iannitti DA. Survival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection. HPB (Oxford) 2014;16:1102-9. [PMID: 24964271 DOI: 10.1111/hpb.12300] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
37 O’Connor DB, Burke JP, Hegarty J, McCormick AP, Nolan N, Hoti E, Maguire D, Geoghegan J, Traynor O. Liver transplantation for hepatocellular carcinoma in Ireland: Pre-operative alpha-fetoprotein predicts tumour recurrence in a 14-year single-centre national experience. World J Transplant 2016; 6(2): 396-402 [PMID: 27358785 DOI: 10.5500/wjt.v6.i2.396] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
38 Yin J, Bo WT, Sun J, Xiang X, Lang JY, Zhong JH, Li LQ. New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Clin Transl Hepatol. 2017;5:169-176. [PMID: 28660155 DOI: 10.14218/jcth.2016.00071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
39 Dixon E, Abdalla E, Schwarz RE, Vauthey JN. AHPBA/SSO/SSAT sponsored Consensus Conference on Multidisciplinary Treatment of Hepatocellular Carcinoma. HPB (Oxford). 2010;12:287-288. [PMID: 20590900 DOI: 10.1111/j.1477-2574.2010.00184.x.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Renner P, Schuhbaum J, Kroemer A, Zeman F, Loss M, Lang SA, Geissler EK, Schlitt HJ, Farkas SA. Morbidity of hepatic resection for intermediate and advanced hepatocellular carcinoma. Langenbecks Arch Surg 2016;401:43-53. [DOI: 10.1007/s00423-015-1359-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
41 Earl TM, Chapman WC. Conventional Surgical Treatment of Hepatocellular Carcinoma. Clinics in Liver Disease 2011;15:353-70. [DOI: 10.1016/j.cld.2011.03.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
42 Dixon E, Abdalla E, Schwarz RE, Vauthey JN. AHPBA/SSO/SSAT sponsored Consensus Conference on Multidisciplinary Treatment of Hepatocellular Carcinoma. HPB (Oxford) 2010;12:287-8. [PMID: 20590900 DOI: 10.1111/j.1477-2574.2010.00184.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
43 Yan S, Xu D, Sun B. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci 2012;57:3026-31. [PMID: 22585384 DOI: 10.1007/s10620-012-2212-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
44 Hyun MH, Lee YS, Kim JH, Lee CU, Jung YK, Seo YS, Yim HJ, Yeon JE, Byun KS. Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: A meta-analysis of high-quality studies. Hepatology. 2018;68:977-993. [PMID: 29543988 DOI: 10.1002/hep.29883] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 16.5] [Reference Citation Analysis]
45 Dunbar JK, Dillon J, Garden OJ, Brewster DH. Increasing survival of hepatocellular carcinoma patients in Scotland: a review of national cancer registry data. HPB (Oxford) 2013;15:279-85. [PMID: 23458384 DOI: 10.1111/j.1477-2574.2012.00567.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
46 Yan W, Chang Y, Liang X, Cardinal JS, Huang H, Thorne SH, Monga SP, Geller DA, Lotze MT, Tsung A. High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology. 2012;55:1863-1875. [PMID: 22234969 DOI: 10.1002/hep.25572] [Cited by in Crossref: 161] [Cited by in F6Publishing: 152] [Article Influence: 16.1] [Reference Citation Analysis]
47 Kang K, Song SK, Chung CW, Park Y. Value of surgical resection compared to transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein tumor thrombus: A meta-analysis of hazard ratios from five observational studies. Ann Hepatobiliary Pancreat Surg 2020;24:243-51. [PMID: 32843588 DOI: 10.14701/ahbps.2020.24.3.243] [Reference Citation Analysis]
48 Wilson GC, Geller DA. Evolving Surgical Options for Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2019;28:645-61. [DOI: 10.1016/j.soc.2019.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
49 Bhattacharya S, Mondal L, Mukherjee B, Dutta L, Ehsan I, Debnath MC, Gaonkar RH, Pal MM, Majumdar S. Apigenin loaded nanoparticle delayed development of hepatocellular carcinoma in rats. Nanomedicine 2018;14:1905-17. [PMID: 29802937 DOI: 10.1016/j.nano.2018.05.011] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
50 Liu Y, Yan W, Tohme S, Chen M, Fu Y, Tian D, Lotze M, Tang D, Tsung A. Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. J Hepatol. 2015;63:114-121. [PMID: 25681553 DOI: 10.1016/j.jhep.2015.02.009] [Cited by in Crossref: 90] [Cited by in F6Publishing: 95] [Article Influence: 12.9] [Reference Citation Analysis]
51 Chow PK. Resection for hepatocellular carcinoma: is it justifiable to restrict this to the American Association for the Study of the Liver/Barcelona Clinic for Liver Cancer criteria? J Gastroenterol Hepatol. 2012;27:452-457. [PMID: 22142283 DOI: 10.1111/j.1440-1746.2011.07034.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
52 Liu H, Chen H, Wu X, Sun Y, Wang Y, Zeng Y, Chen G, Liu X, Xing X, Zhao B, Liu J. The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection. Cancer Manag Res 2019;11:2935-46. [PMID: 31114342 DOI: 10.2147/CMAR.S190561] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
53 Gong SC, Cho MY, Lee SW, Kim SH, Kim MY, Baik SK. The meaning of gross tumor type in the aspects of cytokeratin 19 expression and resection margin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2016;31:206-12. [PMID: 26212571 DOI: 10.1111/jgh.13063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
54 Chen RC, Yi PP, Zhou RR, Xiao MF, Huang ZB, Tang DL, Huang Y, Fan XG. The role of HMGB1-RAGE axis in migration and invasion of hepatocellular carcinoma cell lines. Mol Cell Biochem. 2014;390:271-280. [PMID: 24510323 DOI: 10.1007/s11010-014-1978-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 55] [Article Influence: 6.1] [Reference Citation Analysis]
55 Beane JD, Hyer M, Mehta R, Onuma AE, Gleeson EM, Thompson VM, Pawlik TM, Pitt HA. Optimal hepatic surgery: Are we making progress in North America? Surgery 2021:S0039-6060(21)00636-X. [PMID: 34325906 DOI: 10.1016/j.surg.2021.06.028] [Reference Citation Analysis]
56 Zhong JH, Wu FX, Li H. Hepatic resection associated with good survival for selected patients with multinodular hepatocellular carcinoma. Tumour Biol 2014;35:8355-8. [PMID: 25195949 DOI: 10.1007/s13277-014-2571-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
57 Zhang W, Liu C, Tan Y, Jiang L, Yan L, Yang J, Wen T. Role of liver resection in treating intermediate and advanced stage adolescent and young adult hepatocellular carcinoma patients: A propensity-matching cohort study. International Journal of Surgery 2018;54:259-64. [DOI: 10.1016/j.ijsu.2018.03.051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
58 Martinez-Mier G, Esquivel-Torres S, Medina Granados JP, Luna-Castillo M, Castillo-Chiquete R, Calzada-Grijalva JF, Gonzalez-Velazquez F. [Presentation, staging, and outcome of patients with hepatocellular carcinoma at a center in Veracruz, Mexico]. Rev Gastroenterol Mex 2014;79:171-9. [PMID: 25236795 DOI: 10.1016/j.rgmx.2014.05.007] [Reference Citation Analysis]
59 Knab LM, Salem R, Mahvi DM. Minimally invasive therapies for hepatic malignancy. Curr Probl Surg 2013;50:146-79. [PMID: 23507316 DOI: 10.1067/j.cpsurg.2013.01.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
60 Zaydfudim V, Smoot RL, Clark CJ, Kendrick ML, Que FG, Farnell MB, Nagorney DM. Role of operative therapy in non-cirrhotic patients with metastatic hepatocellular carcinoma. J Gastrointest Surg 2012;16:1516-23. [PMID: 22644447 DOI: 10.1007/s11605-012-1918-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
61 Pugalenthi A, Cutter CS, Fong Y. Current treatment for small (< 5 cm) hepatocellular carcinoma: evolving roles for ablation and resection. Adv Surg 2014;48:97-114. [PMID: 25293610 DOI: 10.1016/j.yasu.2014.05.012] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
62 Ross SW, Seshadri R, Walters AL, Augenstein VA, Heniford BT, Iannitti DA, Martinie JB, Vrochides D, Swan RZ. Mortality in hepatectomy: Model for End-Stage Liver Disease as a predictor of death using the National Surgical Quality Improvement Program database. Surgery 2016;159:777-92. [PMID: 26474653 DOI: 10.1016/j.surg.2015.08.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
63 Aloia TA, Hemming A, Schwartz M. Surgical treatment of hepatocellular cancer: expert consensus conference. HPB (Oxford) 2010;12:311-2. [PMID: 20590904 DOI: 10.1111/j.1477-2574.2010.00188.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
64 Tian H, Cao S, Hu M, Wang Y, Fu Q, Pan Y, Qin T. Identification of predictive factors in hepatocellular carcinoma outcome: A longitudinal study. Oncol Lett 2020;20:765-73. [PMID: 32566003 DOI: 10.3892/ol.2020.11581] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 Zhang H, Yuan SX, Dai SY, Zhang JM, Huang X, Lu CD, Lu JH, Wu FQ, Lau WY, Wu MC, Yang T, Shen F. Tumor size does not independently affect long-term survival after curative resection of solitary hepatocellular carcinoma without macroscopic vascular invasion. World J Surg 2014;38:947-57. [PMID: 24258262 DOI: 10.1007/s00268-013-2365-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
66 Zhou J, Ling G, Cao J, Ding X, Liao X, Wu M, Zhou X, Xu H, Long Q. Transcatheter Intra-Arterial Infusion Combined with Interventional Photothermal Therapy for the Treatment of Hepatocellular Carcinoma. Int J Nanomedicine 2020;15:1373-85. [PMID: 32184592 DOI: 10.2147/IJN.S233989] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Wege H, Li J, Ittrich H. Treatment Lines in Hepatocellular Carcinoma. Visc Med 2019;35:266-72. [PMID: 31602390 DOI: 10.1159/000501749] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]